Consequently, GLP‐1 RAs are now in advanced clinical development for the treatment of chronic kidney disease, broader cardiovascular risk reduction, metabolic liver disease and Alzheimer's disease. This evidence concerns the gene GCG and early-onset autosomal dominant Alzheimer disease.